Latest Histone deacetylase inhibitor Stories
Interim Data from 33 Evaluable Patients to be Presented at ASH on Saturday SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc.
SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S.
Studies Support Ongoing Clinical Strategy of Using Syndax's Entinostat as Epigenetic Priming to Immune Therapy WALTHAM, Mass., July 30, 2014 /PRNewswire/ -- Syndax Pharmaceuticals,
Transparency Market Research has added a new report titled "Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to
SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis
New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc.
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S.
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh,
- A transitional zone between two communities containing the characteristic species of each.